James N Gerson1, Stefan K Barta2. 1. Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. 2. Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. Stefan.barta@pennmedicine.upenn.edu.
Abstract
PURPOSE OF REVIEW: Mantle cell lymphoma is a CD5+ non-Hodgkin lymphoma associated with suboptimal outcome. Young, fit patients are generally offered intensive induction followed by autologous hematopoietic cell transplantation (AHCT) in first remission. Some patients may not benefit from this strategy. RECENT FINDINGS: Recent studies have investigated the role of AHCT in the modern era. First, an analysis of the National Cancer Database demonstrated improved progression-free survival (PFS) for consolidative AHCT. Second, a multi-center study associated consolidative AHCT with improved PFS even after propensity-weighted analysis. Improved overall survival (OS) for certain subgroups was suggested. Third, patients with p53 mutations derive little benefit from AHCT. Finally, retrospective series suggest certain high-risk patients may be considered for allogenic HCT. AHCT consolidation in first remission is associated with improved PFS even after adjustment for disease severity. An overall survival benefit has not been definitively shown. Patients with p53 mutations should be treated with novel agents.
PURPOSE OF REVIEW: Mantle cell lymphoma is a CD5+ non-Hodgkin lymphoma associated with suboptimal outcome. Young, fit patients are generally offered intensive induction followed by autologous hematopoietic cell transplantation (AHCT) in first remission. Some patients may not benefit from this strategy. RECENT FINDINGS: Recent studies have investigated the role of AHCT in the modern era. First, an analysis of the National Cancer Database demonstrated improved progression-free survival (PFS) for consolidative AHCT. Second, a multi-center study associated consolidative AHCT with improved PFS even after propensity-weighted analysis. Improved overall survival (OS) for certain subgroups was suggested. Third, patients with p53 mutations derive little benefit from AHCT. Finally, retrospective series suggest certain high-risk patients may be considered for allogenic HCT. AHCT consolidation in first remission is associated with improved PFS even after adjustment for disease severity. An overall survival benefit has not been definitively shown. Patients with p53 mutations should be treated with novel agents.
Authors: I F Khouri; M S Lee; J Romaguera; N Mirza; H Kantarjian; M Korbling; M Albitar; S Giralt; B Samuels; P Anderlini; J Rodriguez; B von Wolff; J Gajewski; F Cabanillas; R Champlin Journal: Ann Oncol Date: 1999-11 Impact factor: 32.976
Authors: Martin Dreyling; Georg Lenz; Eva Hoster; Achiel Van Hoof; Christian Gisselbrecht; Rudolf Schmits; Bernd Metzner; Lorenz Truemper; Marcel Reiser; Hjalmar Steinhauer; Jean-Michel Boiron; Marc A Boogaerts; Ali Aldaoud; Vittorio Silingardi; Hanneke C Kluin-Nelemans; Joerg Hasford; Reza Parwaresch; Michael Unterhalt; Wolfgang Hiddemann Journal: Blood Date: 2004-12-09 Impact factor: 22.113
Authors: Jorge E Romaguera; Luis Fayad; Maria A Rodriguez; Kristine R Broglio; Frederick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Andreas H Sarris; Nam H Dang; Michael Wang; Virginia Beasley; L Jeffrey Medeiros; Ruth L Katz; Harish Gagneja; Barry I Samuels; Terry L Smith; Fernando F Cabanillas Journal: J Clin Oncol Date: 2005-09-06 Impact factor: 44.544
Authors: Georg Lenz; Martin Dreyling; Eva Hoster; Bernhard Wörmann; Ulrich Dührsen; Bernd Metzner; Hartmut Eimermacher; Andreas Neubauer; Hannes Wandt; Hjalmar Steinhauer; Sonja Martin; Else Heidemann; Ali Aldaoud; Reza Parwaresch; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann Journal: J Clin Oncol Date: 2005-01-24 Impact factor: 44.544
Authors: D Decaudin; N Brousse; P Brice; C Haioun; J H Bourhis; P Morel; A Van Hoof; B Souleau; B Quesnel; C Gisselbrecht Journal: Bone Marrow Transplant Date: 2000-02 Impact factor: 5.483
Authors: Elisabeth Vandenberghe; Carmen Ruiz de Elvira; Fausto R Loberiza; E Conde; A López-Guillermo; C Gisselbrecht; F Guilhot; Julie M Vose; Koen van Biesen; J Douglas Rizzo; Dennis D Weisenburger; Peter Isaacson; Mary M Horowitz; Anthony H Goldstone; Hillard M Lazarus; Norbert Schmitz Journal: Br J Haematol Date: 2003-03 Impact factor: 6.998
Authors: Eva Hoster; Martin Dreyling; Wolfram Klapper; Christian Gisselbrecht; Achiel van Hoof; Hanneke C Kluin-Nelemans; Michael Pfreundschuh; Marcel Reiser; Bernd Metzner; Hermann Einsele; Norma Peter; Wolfram Jung; Bernhard Wörmann; Wolf-Dieter Ludwig; Ulrich Dührsen; Hartmut Eimermacher; Hannes Wandt; Joerg Hasford; Wolfgang Hiddemann; Michael Unterhalt Journal: Blood Date: 2007-10-25 Impact factor: 22.113
Authors: Timothy C Greiner; Chiranjib Dasgupta; Vincent V Ho; Dennis D Weisenburger; Lynette M Smith; James C Lynch; Julie M Vose; Kai Fu; James O Armitage; Rita M Braziel; Elias Campo; Jan Delabie; Randy D Gascoyne; Elaine S Jaffe; Hans K Muller-Hermelink; German Ott; Andreas Rosenwald; Louis M Staudt; Michael Y Im; Mazen W Karaman; Brian L Pike; Wing C Chan; Joseph G Hacia Journal: Proc Natl Acad Sci U S A Date: 2006-02-03 Impact factor: 11.205
Authors: Ingrid Glimelius; Karin E Smedby; Alexandra Albertsson-Lindblad; Michael J Crowther; Sandra Eloranta; Mats Jerkeman; Caroline E Weibull Journal: Blood Adv Date: 2021-03-23